uniQure N.V. (QURE) News
Follow uniQure N.V. (QURE) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 45 public stories across 16 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
uniQure Reports Quarterly Results for Period Ended September 30
The LSEG machine-generated summary provides no earnings figures or other results in the supplied text.
EQUITY | Nov 04, 2026, 02:32 PM UTC
M
UniQure Q3 Loss Narrows, Revenue Increases
UniQure reported a third-quarter loss of $0.88 per share.
EQUITY | Nov 04, 2026, 02:28 PM UTC
M
uniQure Reports Q3 2026 Revenue of $5.2 Million, Net Loss of $61.2 Million
The company reported a net loss of $0.88 per ordinary share and $768.4 million in cash, cash equivalents and investment securities at September 30, 2026. It expects the funds to support operations into 2030.
EQUITY | Nov 04, 2026, 12:35 PM UTC
M
uniQure Q3 net loss narrows 24% to USD 61.22 million
EQUITY | Nov 04, 2026, 12:31 PM UTC
M
uniQure Q3 Revenue Misses Estimates
EQUITY | Nov 04, 2026, 12:23 PM UTC
L
UniQure Says FDA Accepts Application for Huntington’s Gene Therapy
UniQure said the FDA accepted an application for its potential Huntington’s disease gene therapy.
REGULATION | Nov 02, 2026, 01:06 PM UTC
M
FDA Grants Priority Review to uniQure Huntington’s Gene Therapy
The FDA granted priority review to uniQure’s Huntington’s disease gene therapy.
REGULATION | Nov 02, 2026, 12:23 PM UTC
M
uniQure to Announce Third-Quarter 2026 Financial Results
EQUITY | Oct 28, 2026, 11:07 AM UTC
H
Hewlett Packard Enterprise, Capital Bancorp, FormFactor And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Wednesday. Shares of Hewlett Packard Enterprise Co (NYSE: HPE ) rose during Wednesday’s session after the company announced it raised its FY27
LIVE | Sep 30, 2026, 01:55 PM UTC
L
uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE)
uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE)
NEWS | Sep 30, 2026, 12:12 AM UTC
L
QURE Stock Clocks Worst Day In Over 10 Months: Four-Year Huntington’s Data Spooks Investors Despite Stronger Three-Year Filing Data
Shares of uniQure (QURE) collapsed 37% on Tuesday after four-year results from its Huntington’s gene therapy study missed a key statistical test, even as the company said the treatment still slowed decline, and analysts
EQUITY | Sep 29, 2026, 10:08 PM UTC
H
Crude Oil Down 1%; US Job Openings Fall In August
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 50 points on Tuesday. The Dow traded down 0.65% to 51,144.93 while the NASDAQ fell 0.21% to 26,763.71. The S&P 500 also fell, drop
LIVE | Sep 29, 2026, 04:01 PM UTC
H
Dow Tumbles 100 Points; Carnival Posts Upbeat Q3 Earnings
U.S. stocks traded mixed this morning, with the Dow Jones falling more than 100 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.21% to 51,374.54 while the NASDAQ rose 0.03% to 26,828.76. Th
LIVE | Sep 29, 2026, 02:13 PM UTC
L
UniQure Insists Huntington's Drug Is Still on Track as Stock Plunges 48% — Barrons.com
By Mackenzie TatananniUniQure stock plunged on Tuesday after the drugmaker issued a disappointing update regarding its closely watched candidate for Huntington's disease.Amsterdam-based uniQure reported that its experime
EQUITY | Sep 29, 2026, 01:26 PM UTC
L
uniQure: AMT-130 phase I/II data show sustained functional benefit at 36—48 months
uniQure reported AMT-130 high-dose data showing continued slowing of Huntington’s disease progression at 36 and 48 months.Key Highlights:Original SEC Filing: uniQure N.V. [ QURE ] - 8-K - Sep. 29, 2026This is an AI-power
REGULATION | Sep 29, 2026, 01:13 PM UTC
L
UniQure Stock Drops After Huntington's Drug Results Disappoint at 4-Year Mark
By Kelly CloonanShares of uniQure slid after patients treated with its Huntington's disease drug in a recent study no longer showed a statistically significant slowdown in disease-induced decline after four years.The sto
EQUITY | Sep 29, 2026, 01:12 PM UTC
L
QURE Stock Is On Track To Shed About Half Its Market Cap Despite Encouraging Huntington’s Disease Data — Here’s What Investors Need To Know
Shares of uniQure (QURE) crashed more than 50% in pre-market trading on Tuesday after data for its experimental Huntington’s disease gene therapy raised questions about how well its treatment effect holds up over time.Th
EQUITY | Sep 29, 2026, 12:59 PM UTC
L
UniQure's Huntington's therapy fails to significantly slow disease progression, shares plunge
UniQure NASDAQ:QURE said its gene therapy for Huntington's disease fell short of statistical significance on the main goal of slowing disease progression in a four-year analysis, sending its U.S.-listed shares plummeting
EQUITY | Sep 29, 2026, 11:55 AM UTC
L
UniQure's Huntington's therapy fails to significantly slow disease progression in trial
UniQure NASDAQ:QURE, NASDAQ:QURE said on Tuesday its Huntington's treatment showed 44% slowing of disease progression, but did not reach statistical significance in an ongoing early-to-mid-stage trial.U.S.-listed shares
EQUITY | Sep 29, 2026, 11:35 AM UTC
L
uniQure N.V. (QURE) Posts New AMT-130 Data Showing Slower HD Progression
uniQure reported Phase I/II data for AMT-130 in Huntington’s disease: at 36 months in 15 high-dose patients, cUHDRS showed 80% slowing (nominal p=0.005) and TFC 67% (nominal p=0.011) vs external controls; at 48 months in
NEWS | Sep 29, 2026, 11:18 AM UTC
L
uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec (AMT-130) in Huntington’s Disease Showing Continued Slowing of Disease Progression
~ In 12 high-dose patients at 48 months, both cUHDRS and TFC continued to demonstrate meaningful slowing of disease progression and clear dose-dependent response; the primary endpoint of cUHDRS showed 44% slowing of dise
NEWS | Sep 29, 2026, 11:18 AM UTC
M
uniQure shares swing after AMT-130 approval filing; Blair resumes coverage
uniQure (QURE) shares swung after the company filed for U.S. and U.K. approval of its Huntington’s disease gene therapy, AMT-130. William Blair resumed coverage with an Outperform rating and a $73 fair value estimate.
EQUITY | Sep 02, 2026, 10:36 PM UTC
M
uniQure applies for U.S. approval after FDA reverses stance
uniQure said it has applied for U.S. approval of its experimental Huntington’s disease gene therapy after the FDA reversed its earlier position; shares were up 5% in premarket trading.
REGULATION | Sep 02, 2026, 12:22 PM UTC
M
uniQure submits FDA and MHRA filings for AMT-130
uniQure submitted a BLA to the FDA seeking accelerated approval and an MAA to the MHRA for ifezuntirgene inilparvovec (AMT-130), supported by three-year Phase I/II data showing slowed disease progression.
REGULATION | Sep 02, 2026, 11:13 AM UTC
L
uniQure submits biologics license application for ifezuntirgene inilparvovec in Huntington’s
uniQure (QURE) announced submission of a Biologics License Application for ifezuntirgene inilparvovec (AMT-130) in Huntington’s disease.
EQUITY | Sep 02, 2026, 11:07 AM UTC
H
RBC Reiterates QURE Outperform
RBC reiterates QURE Outperform rating
EQUITY | Jul 30, 2026, 11:06 AM UTC
H
QURE Upgraded to Outperform
QURE upgraded to Outperform
EQUITY | Jul 30, 2026, 11:05 AM UTC
H
HSBC, Jefferies, Mizuho Upgrade Stocks
Multiple stocks upgraded by analysts
EQUITY | Jul 30, 2026, 10:41 AM UTC
L
QURE +11% on Q2 Revenue Beat
QURE beats Q2 revenue estimates
EARNINGS | Jul 29, 2026, 01:34 PM UTC
H
Some earnings movers to upside from today, premarket: AVTR +13% LFUS +11% GEHC +9% GNRC +9% HAYW +8% OPCH +6% APH +6% QURE +6% E +6%
Some earnings movers to upside from today, premarket: AVTR +13% LFUS +11% GEHC +9% GNRC +9% HAYW +8% OPCH +6% APH +6% QURE +6% E +6%
EARNINGS | Jul 29, 2026, 12:58 PM UTC
L
QURE rises after Q2 revenue beat
QURE beats Q2 revenue estimates
EARNINGS | Jul 29, 2026, 11:33 AM UTC
L
QURE - uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update
QURE - uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update
EARNINGS | Jul 29, 2026, 11:05 AM UTC
L
Uniqure Insider Sold Shares Worth $952,051, According to a Recent SEC Filing
() -- Matthew C Kapusta, Director, CEO, and Managing Director, on July 02, 2026, sold 21,082 shares in Uniqure (QURE) for $952,051. Following the Form 4 filing with the SEC, Kapusta has control over a total of 519,227 or
REGULATION | Jul 07, 2026, 08:54 PM UTC
L
Uniqure Insider Sold Shares Worth $983,030, According to a Recent SEC Filing
() -- Jack Kaye, Director, on June 30, 2026, sold 21,167 shares in Uniqure (QURE) for $983,030. Following the Form 4 filing with the SEC, Kaye has control over a total of 25,996 ordinary shares of the company, with 25,99
REGULATION | Jul 02, 2026, 09:04 PM UTC
M
CAPR Falls 13%
Capricor Therapeutics stock is trading lower after the FDA plans to convene an advisory committee meeting to discuss the company's Biologics License Application for Deramiocel
EQUITY | Jun 26, 2026, 06:06 PM UTC
M
QURE Upsizes Public Offering
uniQure announces closing of upsized public offering and full exercise by underwriters of option to purchase additional shares
EQUITY | Jun 25, 2026, 08:10 PM UTC
M
QURE: Mizuho Raises Target
Mizuho analyst raises uniQure price target to $68 and maintains Outperform rating
EQUITY | Jun 25, 2026, 04:17 PM UTC
M
QURE Prices $225M Offering
uniQure announces pricing of upsized $225 million public offering
EQUITY | Jun 24, 2026, 09:13 AM UTC
M
QURE Prices $225M Offering
uniQure prices upsized $225M public offering of 4,945,055 ordinary shares at $45.50 per share
EQUITY | Jun 24, 2026, 05:51 AM UTC
L
CDNL: Proposes Public Offering
CDNL proposes public offering of common stock
EQUITY | Jun 23, 2026, 09:24 AM UTC
M
CDNL: Proposes Public Offering
CDNL proposes public offering of common stock, among other equity offerings from various companies
EQUITY | Jun 22, 2026, 09:10 PM UTC
M
QURE: Announces $150M Offering
uniQure announces a $150 million offering.
EQUITY | Jun 22, 2026, 08:06 PM UTC
M
QURE Launches $150M Offering
uniQure announces a proposed public offering of $150 million
EQUITY | Jun 22, 2026, 08:01 PM UTC
H
RGNX: FDA Reconsiders Gene Therapy
Regenxbio aligns with FDA on next steps for potential accelerated approval of Navsunli gene therapy
EQUITY | Jun 22, 2026, 01:23 PM UTC
M
QURE: Reports Prelim Data
uniQure announces preliminary data on the first cohort in the Phase I/IIa clinical trial of AMT-260 in refractory mesial temporal lobe epilepsy
EQUITY | Jun 19, 2026, 11:27 AM UTC